Effects of Dietary Polystyrene Microplastics on Anxiety- and Depression-like Behaviors
1 other identifier
interventional
15
1 country
1
Brief Summary
The objective of this clinical trial is to explore the potential impact of dietary polystyrene microplastics on anxiety- and depression-like behaviors in resident physicians. Specifically, the study aims to address two key questions:
- 1.Can dietary polystyrene microplastics induce alterations in the human gut microbiome?
- 2.Can dietary polystyrene microplastics exacerbate anxiety- and depression-like behaviors?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2024
CompletedFirst Submitted
Initial submission to the registry
January 7, 2024
CompletedFirst Posted
Study publicly available on registry
February 8, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 25, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2024
CompletedAugust 22, 2024
August 1, 2024
4 months
January 7, 2024
August 21, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assessing mental status using the depression anxiety stress scales-21 (DASS-21) questionnaire
In this study, the researchers utilized the Chinese version of the Depression Anxiety Stress Scales-21 (DASS-21), a widely recognized and reliable instrument for assessing depression, anxiety, and stress. This comprehensive tool is divided into three sections, each dedicated to evaluating the levels of depression, anxiety, and stress, respectively. The depression scale scores range from 0 to 21, with normal scores falling below 4. Anxiety scores also range from 0 to 21, with normal scores below 3. For stress, scores range from 0 to 18, with scores below 7 considered normal. Higher scores on any of these scales indicate elevated levels of depression, anxiety, or stress. In this research, the DASS-21 was employed to monitor the variations in anxiety and depression-like behaviors among the two groups, both at baseline and after the treatment period.
At the baseline and end of this clinical trial an average of two months. the enrolled participants will be asked to complete the DASS-21 questionnaire.
Secondary Outcomes (1)
Alterations in human gut microbial diversity investigated through 16S rRNA
At the beginning and conclusion of this clinical trial, spanning an average duration of two months, the enrolled participants will be asked to provide fecal samples
Study Arms (2)
The control group
NO INTERVENTIONThe control group, consisting of resident physicians, will use non-disposable plastic tableware (NDPT) provided by hospital canteens for two months.
The exposure group
EXPERIMENTALThe exposure group, also comprising resident physicians, will use disposable plastic tableware (DPT) made of polystyrene, provided by the same hospital canteens for two months
Interventions
Microplastic release from the daily use of disposable plastic materials (e.g., plastic boxes) when holding hot food or drink.
Eligibility Criteria
You may qualify if:
- Volunteer resident physician at the base of Northern Jiangsu Hospital, Yangzhou, China
You may not qualify if:
- received chemotherapy, radiotherapy, or surgery in the 3 -6 months before sampling
- diagnosed with mental illness
- diagnosed with digestive system diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ju Gao
Yangzhou, Jiangsu, 225001, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- M.D.; attending doctor
Study Record Dates
First Submitted
January 7, 2024
First Posted
February 8, 2024
Study Start
January 1, 2024
Primary Completion
April 25, 2024
Study Completion
May 1, 2024
Last Updated
August 22, 2024
Record last verified: 2024-08